We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Hemogenyx Pharmaceuticals Plc | LSE:HEMO | London | Ordinary Share | GB00BYX3WZ24 | ORD GBP0.01 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.025 | 1.68% | 1.515 | 1.48 | 1.55 | 1.50 | 1.48 | 1.50 | 3,138,617 | 16:35:24 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Finance Services | 0 | -3.98M | -0.0035 | -4.23 | 16.9M |
Date | Subject | Author | Discuss |
---|---|---|---|
16/1/2023 15:22 | Ahh look at this. On Target/ David both one poster posting the same messages as they forgot change accounts. Cute. Sour tools. | justaman | |
16/1/2023 15:21 | How long before they pull the rug from under this? | baconlover | |
16/1/2023 15:14 | "HEMO now £40m market cap (advfn have it wrong) and rapidly running out of cash. Long way from starting clinical trials on humans as well, they will be testing on monkeys first which they don't have the cash to do. Whereas EVG a mere £12m cap with £7m+ cash in the bank and proper licencing deals in the bag, with multiple clinical trials underway or starting in the next year. So not too surprising if profits from there are finding their way here." | david gruen | |
16/1/2023 15:08 | You're an idiot. That is all. | justaman | |
16/1/2023 14:00 | I was simply responding to the question. We all know where the liquidity is, and it's not at higher levels. | david gruen | |
16/1/2023 13:33 | Oh dear, poor David got it wrong and sold out to early lol. | davevtsmummy | |
16/1/2023 12:37 | At lower levels when the hot-money capitulates? | david gruen | |
16/1/2023 12:29 | Got to be spike sometime soon, or else where MM`s gonna get any stock ? | steveberyl | |
16/1/2023 12:21 | Did you get spiked Smithie? | baconlover | |
16/1/2023 12:19 | If Vlad had any sense he'd be getting a placing away quick. Get some money in the tank for the long road ahead. | notknowing | |
16/1/2023 11:17 | a buy of 400k & ~200k shares gone thru in recent minutes...11:09 some notable buy trades today ----- My guess is that once the top slicers have finished that this will go up more. | smithie6 | |
16/1/2023 11:16 | 2 dips since today's peak both been bought to create a bounce back | smithie6 | |
16/1/2023 10:37 | 1m at 4.20 | orchestralis | |
16/1/2023 10:22 | This a a 50p stock with the current breakthrough. | hsdeo | |
16/1/2023 10:18 | HEMO : Another 20M volume by 10 am, that's the way | master rsi | |
16/1/2023 10:00 | All shares need sellers to make a market. Means nothing to the main event which is, UP! | steveberyl | |
16/1/2023 09:41 | People selling out too soon | orchestralis | |
16/1/2023 09:39 | 4p hit , profits taken , back in at 3.4 and 6 next target . | jotoha2 | |
16/1/2023 09:02 | Is going places this morning and ADVFN intraday chart is NOT up to date with the movement spread 3.90 v 4p now Last trade 215 09:02:03 4.0 9653 O 3.9 - 4.0 | master rsi | |
15/1/2023 13:08 | From that post, let me re-post one of the link to a page of very interesting info which explains about stuff at cell/virus level. Quite in-depth stuff so phps best read in a silent room with enough time to read it. | smithie6 | |
15/1/2023 13:02 | I will take a look at 8394. Thanks | smithie6 | |
15/1/2023 12:25 | 8394 is a very long read, Old, but still relevant, all your Questions are answered there. Click on each highlighted explanation. The main point about CBR invention is the, Velcro solution. 8394 also explains why HEMO was so cheap. Plus hemo are a very credible company working with some exalted partners. No comparison with SNG, Who did not do as much work as they should have done before clinical trials. SNG failed on many fronts and is unlikely to be worth very much for a long time, if ever. | steveberyl | |
15/1/2023 11:50 | CBR "Our scientists have achieved in vitro proof of concept for a CBR construct that neutralises all known variants of the SARS-CoV-2 virus that causes COVID, and have now completed preparations to test it against live replicating virus in a Biosafety Level 3 facility" can someone translate "achieved in vitro proof of concept" I can not understand or balance the 3 key words used - achieved - proof - concept Has it been proven or is it just a concept ???? ----- " Meanwhile, the Company is conducting in vivo tests to demonstrate that CBR could be used against infectious replicating SARS-CoV-2 virus, including its recent dangerous variants. These tests are being conducted using a biosafety level 3 ("BSL3") facility that belongs to a government-owned institution" Is it correct to guess/assume that 'if' it is proven, ie. it works, that an RNS stating that would put these shares into the stratosphere ? (since it opens the door to creating pharmas to treat/protect against viruses, including HIV, chickenpox, ebola, dengue, Marberg etc etc.) (& I use that word stratosphere intentionally/sincer ====== MD wrote "On the viral front, its potential ability to treat a very wide range of viruses give it the potential to revolutionise the treatment of viral diseases and even to become the means of counteracting biological warfare." - "revolutionise" How much confidence do ppl have in his written text ? "counteract biological warfare" perhaps the MD is angling for the public system (whether health dept. or defence dept) to fund the development trials needed before application/use. --------- The Jenner facility at Oxford Univ. came up with one of the vaccines against the Covid virus, they have been working in R& D to combat viruses for decades, & others have been working on fighting viruses such as Dengue & HIV for decades, with surely many more man years of research, how come they didn't come up with this invention ?? | smithie6 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions